Scientific Publications by FDA Staff
J Immunol 2011 Nov 15;187(10):4935-46
A novel combination immunotherapy for cancer by IL-13Ralpha2-targeted DNA vaccine and immunotoxin in murine tumor models.
Nakashima H, Terabe M, Berzofsky JA, Husain SR, Puri RK
Optimum efficacy of therapeutic cancer vaccines may require combinations that generate effective antitumor immune responses, as well as overcome immune evasion and tolerance mechanisms mediated by progressing tumor. Previous studies showed that IL-13Ralpha2, a unique tumor-associated Ag, is a promising target for cancer immunotherapy. A targeted cytotoxin composed of IL-13 and mutated Pseudomonas exotoxin induced specific killing of IL-13Ralpha2(+) tumor cells. When combined with IL-13Ralpha2 DNA cancer vaccine, surprisingly, it mediated synergistic antitumor effects on tumor growth and metastasis in established murine breast carcinoma and sarcoma tumor models. The mechanism of synergistic activity involved direct killing of tumor cells and cell-mediated immune responses, as well as elimination of myeloid-derived suppressor cells and, consequently, regulatory T cells. These novel results provide a strong rationale for combining immunotoxins with cancer vaccines for the treatment of patients with advanced cancer.
|Category: Journal Article|
|PubMed ID: #22013118|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2011-10-21||Entry Last Modified: 2012-08-29|